Palisade Bio Secures Japan Patent For PALI-2108 For Ulcerative Colitis And Fibrostenotic Crohn's Disease

PALI-2108 is the first and only PDE4 inhibitor in development targeting

the terminal ileum and colon for treatment of ulcerative colitis (UC) and fibrostenotic Crohn's disease (FSCD) to address significant unmet medical needs



Ongoing development of PALI-2108 across FSCD and UC, with Phase 2 IND submission planned for H1 2026

Carlsbad, CA, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that the Japan Patent Office (JPO) has granted a key patent covering PALI-2108, the Company's lead, gut-microbiota-activated PDE4 B/D inhibitor being advanced for fibrostenotic Crohn's disease (FSCD) and moderate to severe ulcerative colitis (UC).

The patent, titled "Gut Microbiota-Activated PDE4 Inhibitor Prodrug," provides composition-of-matter protection for PALI-2108 in Japan. The base patent term extends into 2041 and is eligible for patent term extension based on regulatory review timelines. This issuance expands Palisade Bio's growing global intellectual property estate supporting PALI-2108 and its broader platform of locally activated PDE4 inhibitor prodrugs.